Iron overload in myelodysplastic syndromes (MDS) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-11-25

AUTHORS

Norbert Gattermann

ABSTRACT

Iron overload (IOL) starts to develop in MDS patients before they become transfusion-dependent because ineffective erythropoiesis suppresses hepcidin production in the liver and thus leads to unrestrained intestinal iron uptake. However, the most important cause of iron overload in MDS is chronic transfusion therapy. While transfusion dependency by itself is a negative prognostic factor reflecting poor bone marrow function, the ensuing transfusional iron overload has an additional dose-dependent negative impact on the survival of patients with lower risk MDS. Cardiac dysfunction appears to be important in this context, as a consequence of chronic anemia, age-related cardiac comorbidity, and iron overload. Another potential problem is iron-related endothelial dysfunction. There is some evidence that with increasing age, high circulating iron levels worsen the atherosclerotic phenotype. Transfusional IOL also appears to aggravate bone marrow failure in MDS, through unfavorable effects on mesenchymal stromal cells as well a hematopoietic cells, particularly erythroid precursors. Patient series and clinical trials have shown that the iron chelators deferoxamine and deferasirox can improve hematopoiesis in a minority of transfusion-dependent patients. Analyses of registry data suggest that iron chelation provides a survival benefit for patients with MDS, but data from a prospective randomized clinical trial are still lacking. More... »

PAGES

55-63

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-017-2367-1

DOI

http://dx.doi.org/10.1007/s12185-017-2367-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092991806

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29177643


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Transfusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deferasirox", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deferoxamine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erythropoiesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepcidins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intestinal Mucosa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron Chelating Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron Overload", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transfusion Reaction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gattermann", 
        "givenName": "Norbert", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00277-013-1737-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047672025", 
          "https://doi.org/10.1007/s00277-013-1737-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-014-2274-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032506354", 
          "https://doi.org/10.1007/s00277-014-2274-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2011.13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022181766", 
          "https://doi.org/10.1038/bmt.2011.13"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-011-0988-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050238564", 
          "https://doi.org/10.1007/s12185-011-0988-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-012-1594-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017282293", 
          "https://doi.org/10.1007/s00277-012-1594-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-11-25", 
    "datePublishedReg": "2017-11-25", 
    "description": "Iron overload (IOL) starts to develop in MDS patients before they become transfusion-dependent because ineffective erythropoiesis suppresses hepcidin production in the liver and thus leads to unrestrained intestinal iron uptake. However, the most important cause of iron overload in MDS is chronic transfusion therapy. While transfusion dependency by itself is a negative prognostic factor reflecting poor bone marrow function, the ensuing transfusional iron overload has an additional dose-dependent negative impact on the survival of patients with lower risk MDS. Cardiac dysfunction appears to be important in this context, as a consequence of chronic anemia, age-related cardiac comorbidity, and iron overload. Another potential problem is iron-related endothelial dysfunction. There is some evidence that with increasing age, high circulating iron levels worsen the atherosclerotic phenotype. Transfusional IOL also appears to aggravate bone marrow failure in MDS, through unfavorable effects on mesenchymal stromal cells as well a hematopoietic cells, particularly erythroid precursors. Patient series and clinical trials have shown that the iron chelators deferoxamine and deferasirox can improve hematopoiesis in a minority of transfusion-dependent patients. Analyses of registry data suggest that iron chelation provides a survival benefit for patients with MDS, but data from a prospective randomized clinical trial are still lacking.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12185-017-2367-1", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "107"
      }
    ], 
    "keywords": [
      "transfusional iron overload", 
      "myelodysplastic syndrome", 
      "iron overload", 
      "clinical trials", 
      "lower-risk myelodysplastic syndromes", 
      "chronic transfusion therapy", 
      "risk myelodysplastic syndromes", 
      "survival of patients", 
      "negative prognostic factor", 
      "transfusion-dependent patients", 
      "bone marrow function", 
      "iron chelator deferoxamine", 
      "mesenchymal stromal cells", 
      "bone marrow failure", 
      "cardiac comorbidities", 
      "endothelial dysfunction", 
      "survival benefit", 
      "prognostic factors", 
      "MDS patients", 
      "transfusion dependency", 
      "cardiac dysfunction", 
      "chronic anemia", 
      "patient series", 
      "transfusion therapy", 
      "dose-dependent negative impact", 
      "marrow function", 
      "hepcidin production", 
      "registry data", 
      "intestinal iron uptake", 
      "ineffective erythropoiesis", 
      "atherosclerotic phenotype", 
      "important cause", 
      "patients", 
      "stromal cells", 
      "chelator deferoxamine", 
      "marrow failure", 
      "erythroid precursors", 
      "iron chelation", 
      "iron levels", 
      "dysfunction", 
      "hematopoietic cells", 
      "trials", 
      "overload", 
      "unfavorable effects", 
      "comorbidities", 
      "cells", 
      "anemia", 
      "deferasirox", 
      "syndrome", 
      "therapy", 
      "deferoxamine", 
      "liver", 
      "iron uptake", 
      "erythropoiesis", 
      "survival", 
      "age", 
      "cause", 
      "hematopoiesis", 
      "phenotype", 
      "failure", 
      "uptake", 
      "negative impact", 
      "evidence", 
      "factors", 
      "levels", 
      "minority", 
      "data", 
      "potential problems", 
      "benefits", 
      "effect", 
      "chelation", 
      "function", 
      "consequences", 
      "impact", 
      "analysis", 
      "series", 
      "production", 
      "precursors", 
      "context", 
      "dependency", 
      "problem"
    ], 
    "name": "Iron overload in myelodysplastic syndromes (MDS)", 
    "pagination": "55-63", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092991806"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-017-2367-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29177643"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-017-2367-1", 
      "https://app.dimensions.ai/details/publication/pub.1092991806"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_736.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12185-017-2367-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-017-2367-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-017-2367-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-017-2367-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-017-2367-1'


 

This table displays all metadata directly associated to this object as RDF triples.

222 TRIPLES      21 PREDICATES      126 URIs      113 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-017-2367-1 schema:about N000436f11ba74080bba91b7827258d3c
2 N04f94b665ce34fda8c1fabb219020a5a
3 N11584677f4824a0893afe822ee60e79a
4 N205e56f559d44f1fbd4e7c56ca7a3f78
5 N271054d172814db7a57706b5c33ba6b7
6 N276c0ad5f1d64d7c8a2c896b535f1c57
7 N3fd3f61a268f45fd807c6f17e416df83
8 N62004652749149b386fd0154add6ead3
9 N6ee8b84665d34729881fe74b8ce24b54
10 Nadf7f35c7ba34059af4433f1dc9e4964
11 Nb436556e49bd4c64b5a8ca65dfd441fb
12 Nb6cf8f1d54034e4985ec3c226ae0f220
13 Nf42ea324979a4134936b989c4006d1f3
14 Nf707079f29f4411495e9727a57a74abc
15 Nfaf8c9a47a7d4268a5eb2b5eb2ed87ca
16 anzsrc-for:11
17 anzsrc-for:1102
18 schema:author N3fe112bb1a954904a15d67169a7bd3e3
19 schema:citation sg:pub.10.1007/s00277-012-1594-z
20 sg:pub.10.1007/s00277-013-1737-x
21 sg:pub.10.1007/s00277-014-2274-y
22 sg:pub.10.1007/s12185-011-0988-3
23 sg:pub.10.1038/bmt.2011.13
24 schema:datePublished 2017-11-25
25 schema:datePublishedReg 2017-11-25
26 schema:description Iron overload (IOL) starts to develop in MDS patients before they become transfusion-dependent because ineffective erythropoiesis suppresses hepcidin production in the liver and thus leads to unrestrained intestinal iron uptake. However, the most important cause of iron overload in MDS is chronic transfusion therapy. While transfusion dependency by itself is a negative prognostic factor reflecting poor bone marrow function, the ensuing transfusional iron overload has an additional dose-dependent negative impact on the survival of patients with lower risk MDS. Cardiac dysfunction appears to be important in this context, as a consequence of chronic anemia, age-related cardiac comorbidity, and iron overload. Another potential problem is iron-related endothelial dysfunction. There is some evidence that with increasing age, high circulating iron levels worsen the atherosclerotic phenotype. Transfusional IOL also appears to aggravate bone marrow failure in MDS, through unfavorable effects on mesenchymal stromal cells as well a hematopoietic cells, particularly erythroid precursors. Patient series and clinical trials have shown that the iron chelators deferoxamine and deferasirox can improve hematopoiesis in a minority of transfusion-dependent patients. Analyses of registry data suggest that iron chelation provides a survival benefit for patients with MDS, but data from a prospective randomized clinical trial are still lacking.
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf N44f2368fe58c4c06914b734c0aa3e4d3
30 N481ff99a87844c92bb650738d755964f
31 sg:journal.1076985
32 schema:keywords MDS patients
33 age
34 analysis
35 anemia
36 atherosclerotic phenotype
37 benefits
38 bone marrow failure
39 bone marrow function
40 cardiac comorbidities
41 cardiac dysfunction
42 cause
43 cells
44 chelation
45 chelator deferoxamine
46 chronic anemia
47 chronic transfusion therapy
48 clinical trials
49 comorbidities
50 consequences
51 context
52 data
53 deferasirox
54 deferoxamine
55 dependency
56 dose-dependent negative impact
57 dysfunction
58 effect
59 endothelial dysfunction
60 erythroid precursors
61 erythropoiesis
62 evidence
63 factors
64 failure
65 function
66 hematopoiesis
67 hematopoietic cells
68 hepcidin production
69 impact
70 important cause
71 ineffective erythropoiesis
72 intestinal iron uptake
73 iron chelation
74 iron chelator deferoxamine
75 iron levels
76 iron overload
77 iron uptake
78 levels
79 liver
80 lower-risk myelodysplastic syndromes
81 marrow failure
82 marrow function
83 mesenchymal stromal cells
84 minority
85 myelodysplastic syndrome
86 negative impact
87 negative prognostic factor
88 overload
89 patient series
90 patients
91 phenotype
92 potential problems
93 precursors
94 problem
95 production
96 prognostic factors
97 registry data
98 risk myelodysplastic syndromes
99 series
100 stromal cells
101 survival
102 survival benefit
103 survival of patients
104 syndrome
105 therapy
106 transfusion dependency
107 transfusion therapy
108 transfusion-dependent patients
109 transfusional iron overload
110 trials
111 unfavorable effects
112 uptake
113 schema:name Iron overload in myelodysplastic syndromes (MDS)
114 schema:pagination 55-63
115 schema:productId N229c1c1c717248f287f5aad8434528c4
116 N47a1b2719ae248fca95b6f7b70b0696f
117 N91329b966432462a86584ee6ff6a253a
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092991806
119 https://doi.org/10.1007/s12185-017-2367-1
120 schema:sdDatePublished 2022-08-04T17:06
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N66e39dde93f8410e9364af0e8bd2a88a
123 schema:url https://doi.org/10.1007/s12185-017-2367-1
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N000436f11ba74080bba91b7827258d3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Myelodysplastic Syndromes
129 rdf:type schema:DefinedTerm
130 N04f94b665ce34fda8c1fabb219020a5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Blood Transfusion
132 rdf:type schema:DefinedTerm
133 N11584677f4824a0893afe822ee60e79a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Humans
135 rdf:type schema:DefinedTerm
136 N205e56f559d44f1fbd4e7c56ca7a3f78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Iron
138 rdf:type schema:DefinedTerm
139 N229c1c1c717248f287f5aad8434528c4 schema:name pubmed_id
140 schema:value 29177643
141 rdf:type schema:PropertyValue
142 N271054d172814db7a57706b5c33ba6b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Deferasirox
144 rdf:type schema:DefinedTerm
145 N276c0ad5f1d64d7c8a2c896b535f1c57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Iron Chelating Agents
147 rdf:type schema:DefinedTerm
148 N3fd3f61a268f45fd807c6f17e416df83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Transfusion Reaction
150 rdf:type schema:DefinedTerm
151 N3fe112bb1a954904a15d67169a7bd3e3 rdf:first sg:person.01273447501.34
152 rdf:rest rdf:nil
153 N44f2368fe58c4c06914b734c0aa3e4d3 schema:volumeNumber 107
154 rdf:type schema:PublicationVolume
155 N47a1b2719ae248fca95b6f7b70b0696f schema:name doi
156 schema:value 10.1007/s12185-017-2367-1
157 rdf:type schema:PropertyValue
158 N481ff99a87844c92bb650738d755964f schema:issueNumber 1
159 rdf:type schema:PublicationIssue
160 N62004652749149b386fd0154add6ead3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Triazoles
162 rdf:type schema:DefinedTerm
163 N66e39dde93f8410e9364af0e8bd2a88a schema:name Springer Nature - SN SciGraph project
164 rdf:type schema:Organization
165 N6ee8b84665d34729881fe74b8ce24b54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Benzoates
167 rdf:type schema:DefinedTerm
168 N91329b966432462a86584ee6ff6a253a schema:name dimensions_id
169 schema:value pub.1092991806
170 rdf:type schema:PropertyValue
171 Nadf7f35c7ba34059af4433f1dc9e4964 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Intestinal Mucosa
173 rdf:type schema:DefinedTerm
174 Nb436556e49bd4c64b5a8ca65dfd441fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Liver
176 rdf:type schema:DefinedTerm
177 Nb6cf8f1d54034e4985ec3c226ae0f220 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Hepcidins
179 rdf:type schema:DefinedTerm
180 Nf42ea324979a4134936b989c4006d1f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Erythropoiesis
182 rdf:type schema:DefinedTerm
183 Nf707079f29f4411495e9727a57a74abc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Iron Overload
185 rdf:type schema:DefinedTerm
186 Nfaf8c9a47a7d4268a5eb2b5eb2ed87ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Deferoxamine
188 rdf:type schema:DefinedTerm
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
193 schema:name Cardiorespiratory Medicine and Haematology
194 rdf:type schema:DefinedTerm
195 sg:journal.1076985 schema:issn 0925-5710
196 1865-3774
197 schema:name International Journal of Hematology
198 schema:publisher Springer Nature
199 rdf:type schema:Periodical
200 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
201 schema:familyName Gattermann
202 schema:givenName Norbert
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
204 rdf:type schema:Person
205 sg:pub.10.1007/s00277-012-1594-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1017282293
206 https://doi.org/10.1007/s00277-012-1594-z
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s00277-013-1737-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047672025
209 https://doi.org/10.1007/s00277-013-1737-x
210 rdf:type schema:CreativeWork
211 sg:pub.10.1007/s00277-014-2274-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1032506354
212 https://doi.org/10.1007/s00277-014-2274-y
213 rdf:type schema:CreativeWork
214 sg:pub.10.1007/s12185-011-0988-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050238564
215 https://doi.org/10.1007/s12185-011-0988-3
216 rdf:type schema:CreativeWork
217 sg:pub.10.1038/bmt.2011.13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022181766
218 https://doi.org/10.1038/bmt.2011.13
219 rdf:type schema:CreativeWork
220 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
221 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
222 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...